The history of the sulfa drugs is one of those that have been overshadowed by other stories for quite some time. In the historiography of anti-infective therapies the sulfas have been dwelling in the shadow of fungal antibiotics and of the assumption that it was with the latter that the therapeutic revolution got started during the Second World War. In a more peculiar way the historiography of these medicines has also suffered from a somewhat hagiographic focus---thereby reducing the history of a whole class of drugs to the biography of Gerhard Domagk, a German medical researcher who in 1939 was awarded the Nobel Price for his work on prontosil, the first of these medicines. As Lesch makes clear, however, this is a truly misleading picture. The sulfa drugs, derived from so-called azo-dyes, should better be understood as being part and parcel of a system of invention that had developed in the German pharmaceutical industry from the late nineteenth century. In the specific case of prontosil, Bayer (later part of I G Farben) had pursued a research and development strategy on anti-infective therapy from pre-First World War days. Heinrich Hörlein, a trained chemist, managed this research, bringing together medical people like Domagk with chemists like Joseph Klarer and Fritz Mietzsch. It was meant to be a long term involvement and that was indeed what was needed. What started as an industrial system of invention inspired by Paul Ehrlich\'s views on chemotherapy well before the Great War made very little headway in the 1920s. Thus, the molecule that finally was marketed as prontosil from 1935 onwards encountered the widespread scepticism that had resulted from the futile search for Ehrlich\'s magic bullets. Eventually, the medicine turned out to be effective against such conditions as pneumonia, gonorrhoea and others. Lesch carefully reconstructs the reception in major national drug markets like France, Germany, Great Britain and the US in the late 1930s. For example, in France the introduction of sulfa drugs was slowed down because they were perceived as a threat to a major asset of the nation\'s pharmaceutical industry, therapeutic vaccines.

However, after some hesitation the sulfas got off the mark and with them, as Lesch argues, the therapeutic revolution of the mid-twentieth century. The Second World War cut off the German industry from its export markets while at the same time providing a powerful stimulus for the development of more such medicines in other countries. By the end of war there were literally thousands of known therapeutic molecules of this class and quite a few of these had been successfully marketed as medicines. Lesch singles out the example of sulfapyridine, popularly known as M[&]{.smallcaps}B 693, developed by the British company May [&]{.smallcaps} Baker, and follows in some detail the trajectory of this drug. That the sulfas sparked the therapeutic revolution is not only connected to the fact that they were actually the first of a series of "miracle drugs" that came to be invented between the 1930s and the 1960s, but also that other typical features of that historical phenomenon such as standardization of medical practice and a close link between medical and industrial technologies are shown to be present in their history.

Lesch\'s story essentially closes in the immediate aftermath of the Second World War. It is based on scrupulous and exhaustive archival research and an admirable command of scholarly sources. Although some passages are a demanding read for those with little or no knowledge of chemistry, it is certainly not a specialist account. Instead it is a true eye-opener on the role of sulfa drugs in mid-twentieth-century medicine, placing them firmly in the context of the larger histories of science, medicine and pharmacology. It looks likely to be essential reading for years to come for anyone with a scholarly interest in its subject.
